Royal Caribbean Cruises Ltd. (RCL) Reaches $107.60 After 3.00% Up Move; Last Week Sarepta Therapeutics, Inc. (SRPT) Analysts

June 12, 2018 - By Lawrence Diaz

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 22 have Buy rating, 0 Sell and 5 Hold. Therefore 81% are positive. Sarepta Therapeutics had 120 analyst reports since August 5, 2015 according to SRatingsIntel. SunTrust maintained the stock with “Neutral” rating in Tuesday, September 1 report. Jefferies maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Wednesday, December 14 with “Hold” rating. On Friday, September 1 the stock rating was maintained by RBC Capital Markets with “Buy”. SunTrust maintained the stock with “Buy” rating in Wednesday, March 7 report. William Blair maintained the stock with “Buy” rating in Wednesday, August 26 report. The company was initiated on Tuesday, December 20 by Goldman Sachs. Cowen & Co maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Monday, September 4. Cowen & Co has “Buy” rating and $69.0 target. The rating was upgraded by SunTrust on Monday, September 19 to “Neutral”. As per Wednesday, February 21, the company rating was maintained by JP Morgan. Wedbush downgraded the stock to “Neutral” rating in Thursday, April 21 report. See Sarepta Therapeutics, Inc. (NASDAQ:SRPT) latest ratings:

05/06/2018 Broker: Nomura Rating: Buy New Target: $131.0000 Maintain
18/05/2018 Broker: Goldman Sachs Rating: Buy New Target: $127.0000
15/05/2018 Broker: Leerink Swann Rating: Buy New Target: $121.0000 Maintain
11/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Overweight Old Target: $49 Upgrade
04/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $87 New Target: $91 Maintain
04/05/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $100 New Target: $92 Maintain
03/05/2018 Broker: Oppenheimer Rating: Hold Downgrade
21/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Equal-Weight Old Target: $64 Downgrade
15/03/2018 Broker: SunTrust Rating: Buy New Target: $95.0 Maintain
14/03/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $75 New Target: $95 Maintain

The stock of Royal Caribbean Cruises Ltd. (NYSE:RCL) is a huge mover today! The stock increased 3.78% or $3.92 during the last trading session, reaching $107.6. About 1.40 million shares traded. Royal Caribbean Cruises Ltd. (NYSE:RCL) has declined 0.42% since June 12, 2017 and is downtrending. It has underperformed by 12.99% the S&P500. Some Historical RCL News: ; 26/04/2018 – Royal Caribbean Sees Higher Booking Rates — Earnings Review; 26/04/2018 – Royal Caribbean 1Q Net $218.7M; 12/04/2018 – Talend Connect 2018: New Speakers Include AstraZeneca, Royal Caribbean & TD Bank; 19/03/2018 – RCL Names Adam Goldstein as Vice Chairman, Recognizing Decades of Leadership; 15/05/2018 – Azamara Club Cruises® Unveils 2020 Itineraries; 23/04/2018 – DJ Royal Caribbean Cruises Ltd, Inst Holders, 1Q 2018 (RCL); 19/03/2018 – ROYAL CARIBBEAN CRUISES LTD RCL.N – ROYAL CARIBBEAN EXPECTS IMPACT OF TRANSACTIONS TO FALL IN A RANGE OF $0.12 TO $0.15 A SHARE IN FY2018; 26/04/2018 – Royal Caribbean Sees 2Q Adj EPS $1.85-Adj EPS $1.90; 17/05/2018 – Celebrity Cruises Unveils an Ahh-Inspiring Escape at The Spa on Celebrity Edge; 19/03/2018 – RCL NAMES ADAM GOLDSTEIN AS VICE CHAIRMAN, RECOGNIZING DECADESThe move comes after 9 months positive chart setup for the $22.78 billion company. It was reported on Jun, 12 by Barchart.com. We have $110.83 PT which if reached, will make NYSE:RCL worth $683.52 million more.

More important recent Royal Caribbean Cruises Ltd. (NYSE:RCL) news were published by: Seekingalpha.com which released: “Attractive valuation on Royal Caribbean highlighted” on June 11, 2018, also Seekingalpha.com published article titled: “Royal Caribbean: Lower Risk But Also Less Reward”, Seekingalpha.com published: “Cruise line stocks lower after Morgan Stanley warning” on June 05, 2018. More interesting news about Royal Caribbean Cruises Ltd. (NYSE:RCL) was released by: Streetinsider.com and their article: “Nomura Defends Cruise Line Stability (RCL) (CCL)” with publication date: June 06, 2018.

Royal Caribbean Cruises Ltd. operates as a cruise company. The company has market cap of $22.78 billion. The firm operates cruises under the Royal Caribbean International, Celebrity Cruises, and Azamara Club Cruises brand names. It has a 14.22 P/E ratio. The Royal Caribbean International brand provides a range of itineraries ranging from 2 to 24 nights with options for onboard dining, entertainment, and other onboard activities to various destinations.

Investors sentiment decreased to 1.14 in Q1 2018. Its down 0.18, from 1.32 in 2017Q4. It turned negative, as 49 investors sold Royal Caribbean Cruises Ltd. shares while 178 reduced holdings. 70 funds opened positions while 189 raised stakes. 144.48 million shares or 6.03% less from 153.74 million shares in 2017Q4 were reported. Hartford Management reported 32,603 shares. Focused Wealth Mngmt stated it has 800 shares. State Of Alaska Department Of Revenue stated it has 38,926 shares. Capital Fund Mngmt Sa invested in 0.3% or 422,894 shares. Manufacturers Life Ins Communications The holds 0.02% of its portfolio in Royal Caribbean Cruises Ltd. (NYSE:RCL) for 175,770 shares. Archford Capital Strategies Limited Liability Corp has invested 0% in Royal Caribbean Cruises Ltd. (NYSE:RCL). Laurion Cap Mgmt L P reported 0.04% stake. Cambridge Investment Rech Inc has 0.01% invested in Royal Caribbean Cruises Ltd. (NYSE:RCL) for 8,401 shares. Natl Asset Mgmt Inc accumulated 1,809 shares or 0.03% of the stock. S&Co holds 0.04% in Royal Caribbean Cruises Ltd. (NYSE:RCL) or 2,500 shares. Jupiter Asset Limited, a United Kingdom-based fund reported 127,400 shares. Wellington Mngmt Llp owns 300,600 shares or 0.01% of their US portfolio. Prudential Public Limited Com holds 1.72 million shares or 0.63% of its portfolio. Stifel Financial invested 0.05% of its portfolio in Royal Caribbean Cruises Ltd. (NYSE:RCL). Gotham Asset Ltd Liability has invested 0.12% in Royal Caribbean Cruises Ltd. (NYSE:RCL).

Since December 13, 2017, it had 0 insider purchases, and 10 selling transactions for $19.18 million activity. Another trade for 7,404 shares valued at $996,208 was sold by Lutoff-Perlo Lisa. Bayley Michael W also sold $1.81M worth of Royal Caribbean Cruises Ltd. (NYSE:RCL) on Thursday, December 14. Fain Richard D sold $2.13 million worth of stock or 20,000 shares. Liberty Jason T sold $772,942 worth of Royal Caribbean Cruises Ltd. (NYSE:RCL) on Thursday, January 25.

Analysts await Royal Caribbean Cruises Ltd. (NYSE:RCL) to report earnings on August, 7. They expect $1.89 earnings per share, up 10.53% or $0.18 from last year’s $1.71 per share. RCL’s profit will be $400.20M for 14.23 P/E if the $1.89 EPS becomes a reality. After $1.09 actual earnings per share reported by Royal Caribbean Cruises Ltd. for the previous quarter, Wall Street now forecasts 73.39% EPS growth.

Among 23 analysts covering Royal Caribbean Cruises Ltd. (NYSE:RCL), 16 have Buy rating, 1 Sell and 6 Hold. Therefore 70% are positive. Royal Caribbean Cruises Ltd. had 70 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Royal Caribbean Cruises Ltd. (NYSE:RCL) has “Hold” rating given on Wednesday, August 2 by Deutsche Bank. The rating was maintained by Wedbush with “Buy” on Wednesday, November 8. JP Morgan downgraded the stock to “Neutral” rating in Thursday, October 27 report. The firm has “Buy” rating given on Wednesday, November 8 by Stifel Nicolaus. The stock has “Equal-Weight” rating by Morgan Stanley on Tuesday, January 5. The rating was maintained by JP Morgan on Thursday, January 25 with “Overweight”. The stock has “Outperform” rating by Wedbush on Wednesday, February 3. As per Tuesday, June 7, the company rating was initiated by Sterne Agee CRT. The firm has “Positive” rating by Susquehanna given on Wednesday, February 3. The firm has “Buy” rating given on Monday, November 6 by Wells Fargo.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Bizjournals.com which released: “Biogen’s head of late-stage trials leaves for Sarepta” on June 07, 2018, also Nasdaq.com with their article: “Sarepta Therapeutics to Host R&D Day on Tuesday, June 19, 2018” published on June 08, 2018, Nasdaq.com published: “3 Stocks That Tripled in Just 12 Months” on June 04, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Nasdaq.com and their article: “Biotech ETFs Are the Best Way to Play the Recovering Sector” published on May 30, 2018 as well as Seekingalpha.com‘s news article titled: “EMA’s advisory committee thumbs down on Sarepta’s Exondys” with publication date: June 01, 2018.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $6.38 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

Investors sentiment decreased to 0.97 in Q1 2018. Its down 0.25, from 1.22 in 2017Q4. It worsened, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported. Qs Investors Lc reported 2,664 shares. Canada Pension Plan Invest Board reported 15,800 shares. Stevens Management Ltd Partnership holds 0.02% or 5,455 shares. American Century reported 63,009 shares. Northern Tru reported 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Wexford Cap Limited Partnership stated it has 0.21% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). California State Teachers Retirement Sys holds 0.01% or 93,073 shares. The California-based Wells Fargo And Com Mn has invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Legal And General Gp Public Ltd Limited Liability Company, a United Kingdom-based fund reported 25,080 shares. Benchmark Capital invested 1.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Prudential holds 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 53,215 shares. Sectoral Asset Management holds 327,698 shares. Crow Point Partners Limited Liability Company accumulated 572 shares. Quantitative Inv Mgmt Ltd Liability invested in 144,500 shares or 0.19% of the stock. Stonebridge owns 2,870 shares.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>